Non-HDL-C

More documents

Recommendations

Info

Percent probability for MI within the next 10 years as estimated with the PROCAM CAD calculator 25 21.6 20 15 10 7.5 10.9 5 4.2 0 Baseline Atorvastatin 20 mg Fenofibrate 200 mg Atorvastatin 20 mg + Fenofibrate 200 mg Diabetes Care 2002;25:1198-1202
IS THERE AN ASYMPTOTIC LIMIT FOR LDL AT WHICH CARDIOVASCULAR EVENT RATES APPROXIMATE ZERO
Page 1 and 2: Current Targets and Treatment Gaps
Page 3 and 4: Fasting and Nonfasting TG: Equally
Page 5 and 6: Role of Low HDL-C in Residual Cardi
Page 7 and 8: Association Between LDL-C, Non-HDL-
Page 9 and 10: CHD risk predicted by HDL and LDL i
Page 11 and 12: New CV events in MI patients with n
Page 13: Percentage of patients reaching ADA
Page 17 and 18: CAD risk can be reduced to a maximu
Page 19 and 20: Should both HDL-C and LDL- C be tar
Page 21: Should HDL Raising Be a Target for
Page 28 and 29: Recommendations for management of d
Page 30: NCEP ATPIII, AHA, and ADA: Recommen
Page 33 and 34: NCEP ATP III Guidelines (Cont.) If
Page 35 and 36: American Diabetes Association Stand
Page 37 and 38: Target Levels Risk Level Initiate t
Page 44 and 45: Conclusion Non pharmacological stra

Non-HDL-C

Create successful ePaper yourself

Delete template?

Save as template?